Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 2/20 | 0.52 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.52 |
| ▸ | CYP2A6 | P11509 | 9/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.51 |
| ▸ | CYP2E1 | P05181 | 4/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.51 |
| ▸ | CYP2B6 | P20813 | 4/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.51 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.48 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.48 |
| ▸ | TDO2 | P48775 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.47 |
| ▸ | AXL | P30530 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | WNT1 | P04628 | 1/20 | 0.45 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.45 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7089008 | 0.90 | CYP2A6 (0.51) | CYP11B1CYP11B2CYP2A6CYP3A4CYP2E1 | |
| SCHEMBL29394740 | 0.89 | CYP2A6 (0.61) | CYP11B1CYP11B2CYP2A6CYP3A4CYP2E1 | |
| SCHEMBL27717288 | 0.85 | CYP11B1 (0.49) | CYP11B1CYP11B2CYP2A6CYP3A4CYP2E1 | |
| SCHEMBL18312170 | 0.83 | CYP11B1 (0.59) | CYP11B1CYP11B2CYP2A6CYP3A4CYP2E1 | |
| SCHEMBL25871388 | 0.81 | CYP11B1 (0.54) | CYP11B1CYP11B2CYP2A6CYP3A4CYP2E1 | |
| SCHEMBL21742649 | 0.81 | CYP11B1 (0.54) | CYP11B1CYP11B2CYP2A6CYP3A4CYP2E1 | |
| SCHEMBL30714540 | 0.79 | AXL (0.56) | CYP11B1CYP11B2CYP2A6CYP3A4CYP2E1 | |
| SCHEMBL1439800 | 0.79 | AXL (0.56) | CYP11B1CYP11B2CYP2A6CYP3A4CYP2E1 | |
| SCHEMBL16826222 | 0.78 | CYP2A6 (0.50) | CYP11B1CYP11B2CYP2A6CYP3A4CYP2E1 | |
| SCHEMBL27635537 | 0.77 | DHFR (0.49) | CYP2A6CYP3A4CYP2B6TDO2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8859574-B2 | Compounds and compositions as kinase inhibitors | IRM LLC (BM) | 2014-10-14 | — | — | US | disclosed |
| US-20130310361-A1 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | IRM LLC (BM) | 2013-11-21 | — | — | US | disclosed |
| US-8519129-B2 | Pyrimidine derivatives as kinase inhibitors | IRM LLC (BM) | 2013-08-27 | — | — | US | disclosed |
| US-8445505-B2 | Pyrimidine derivatives as kinase inhibitors | IRM LLC (BM) | 2013-05-21 | — | — | US | disclosed |
| US-8445505-B2 | Pyrimidine derivatives as kinase inhibitors | IRM LLC (BM) | 2013-05-21 | — | — | US | disclosed |
| US-8445505-B2 | Pyrimidine derivatives as kinase inhibitors | IRM LLC (BM) | 2013-05-21 | — | — | US | disclosed |
| EP-2331526-A2 | PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | IRM LLC (BM) | 2011-06-15 | — | — | EP | disclosed |
| US-20110112063-A1 | PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | IRM LLC (BM) | 2011-05-12 | — | — | US | disclosed |
| US-20110112096-A1 | PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | ITM LLC (BM) | 2011-05-12 | — | — | US | disclosed |
| US-20110112096-A1 | PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | ITM LLC (BM) | 2011-05-12 | — | — | US | disclosed |
| US-20110112096-A1 | PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | ITM LLC (BM) | 2011-05-12 | — | — | US | disclosed |
| EP-2318392-A2 | PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | IRM LLC (BM) | 2011-05-11 | — | — | EP | disclosed |
| WO-2010002655-A2 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | IRM LLC (BM) | 2010-01-07 | — | — | WO | disclosed |
| WO-2009158431-A2 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | IRM LLC (BM) | 2009-12-30 | — | — | WO | disclosed |
| WO-2009158431-A2 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | IRM LLC (BM) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130310361-A1 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | IGF1R, IRS1, IP6K1 | CYP11B1 3762/4885CYP11B2 4249/4885CYP2A6 3653/4885 |
| US-20110112096-A1 | PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | IGF1R, TYMP, PDXK | CYP11B1 3256/4885CYP11B2 3526/4885CYP2A6 2951/4885 |
| US-20110112063-A1 | PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | IGF1R, TYMP, PDXK | CYP11B1 3374/4885CYP11B2 3784/4885CYP2A6 3144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.